Aspergillus Mold Allergy Treatment: Why Immunotherapy Isn't the Answer

Aspergillus immunotherapy is not recommended because the evidence is insufficient and the biology is challenging. A. fumigatus produces 30 characterized allergens including multiple serine proteases that degrade other proteins when mixed, making stable standardized extracts very difficult to produce. ABPA involves overlapping IgE, IgG immune complex, and eosinophilic mechanisms simultaneously — immunotherapy, which works by inducing IgE tolerance, cannot address all these pathways. Small uncontrolled series exploring SCIT in Aspergillus-sensitized asthmatic patients have shown mixed results. This contrasts sharply with Alternaria, where multiple DBPC-RCTs support both SCIT and SLIT. For ABPA, the disease-modifying options are prednisolone, itraconazole, and biologics — not immunotherapy.

Allergic bronchopulmonary aspergillosis (ABPA) is a complex bronchopulmonary disease caused by a hypersensitive immune response to Aspergillus fumigatus colonizing the bronchi — not just airway sensitization. Simple Aspergillus allergy means IgE sensitization to Aspergillus proteins producing rhinitis or mild asthma, similar to any other mold allergy. ABPA requires both sensitization AND specific disease criteria: total IgE ≥500 IU/mL, elevated Aspergillus-specific IgG, blood eosinophilia ≥500 cells/µL, and characteristic CT findings including mucus plugging or central bronchiectasis. ABPA predominantly affects patients with pre-existing asthma or cystic fibrosis and requires specific treatment beyond standard allergy pharmacotherapy.

ABPA diagnosis follows the 2024 ISHAM revised criteria, which require: (1) a predisposing condition (asthma or cystic fibrosis), (2) A. fumigatus-specific IgE ≥0.35 kUA/L, (3) total serum IgE ≥500 IU/mL, plus at least two of: elevated A. fumigatus-specific IgG, blood eosinophils ≥500 cells/µL, or suggestive CT imaging. High-attenuation mucus (HAM) on CT chest is pathognomonic — it confirms ABPA alone without meeting other criteria. Component-resolved diagnostics with rAsp f 4 and rAsp f 6 provide 99.2% ABPA-specific diagnostic specificity. This diagnostic framework lowered the IgE threshold from 1,000 to 500 IU/mL, improving sensitivity from 91% to 98% and catching more cases before severe lung damage develops.

Omalizumab (Xolair), an anti-IgE monoclonal antibody, has the longest clinical track record for refractory ABPA, consistently reducing exacerbation rates, IgE levels, and prednisolone requirements across multiple published case series. Anti-IL-5 agents — mepolizumab (Nucala) and benralizumab (Fasenra) — reduce the eosinophilic component of ABPA and have shown reductions in mucus plug frequency and exacerbation rates. Dupilumab (Dupixent), which targets both IL-4 and IL-13 signaling, has limited but promising early data. All biologics for ABPA are off-label (not FDA-approved specifically for ABPA) and require specialist prescription and prior authorization due to cost. They are typically reserved for patients with documented failure or intolerable side effects from prednisolone and itraconazole.

No — sublingual immunotherapy (SLIT drops) has the same evidence gap as allergy shots for Aspergillus allergy and ABPA. Both SCIT and SLIT work via the same IgE-desensitization mechanism, and neither has been validated for Aspergillus in controlled trials. The technical and biological challenges that prevent Aspergillus SCIT development (protease-rich unstable extracts, multi-mechanism disease) apply equally to SLIT. However, SLIT remains relevant for Aspergillus-sensitized patients who also have confirmed sensitivities to other allergens — house dust mites, Alternaria, or pet dander — where validated SLIT evidence exists and concurrent allergen burden reduction may improve overall disease control.

Itraconazole helps ABPA by reducing the Aspergillus fungal burden colonizing the bronchi — not by treating an infection in the traditional sense, but by reducing the continuous antigen stimulation that drives the ABPA immune response. A. fumigatus colonizes asthmatic and cystic fibrosis airways without causing invasive infection; however, the ongoing presence of living fungi continuously presenting allergens to the sensitized immune system perpetuates the IgE, IgG, and eosinophilic responses driving ABPA. By suppressing fungal growth with itraconazole, the antigen load decreases, total IgE falls, eosinophilia resolves, and ABPA activity diminishes. This is a steroid-sparing strategy — particularly valuable for patients with frequent relapses who would otherwise require repeated prolonged prednisolone courses.

No — Aspergillus allergy and Aspergillus infection (invasive aspergillosis or CPA) are fundamentally different conditions with different patient populations and treatments. Aspergillus allergy, including ABPA, occurs in immunocompetent atopic individuals whose immune systems overreact to Aspergillus antigens — the fungus is not actually invading tissue. Invasive aspergillosis occurs in severely immunocompromised patients (neutropenia, HSCT, SOT) where A. fumigatus actively invades blood vessels and tissues with mortality of 25 to 90%. The treatments are completely different: allergy management (prednisolone, itraconazole for ABPA) versus aggressive antifungal therapy with voriconazole first-line for invasive disease. ABPA can, however, predispose to chronic pulmonary aspergillosis in patients with established bronchiectatic cavities — a rare overlap between allergic and infectious Aspergillus disease.

Yes — elevated blood eosinophil count (≥500 cells/µL) is one of the diagnostic criteria for ABPA per the 2024 ISHAM guidelines, reflecting the Type 2 eosinophilic inflammatory response driven by IL-4, IL-5, and IL-13 cytokines in ABPA. Eosinophilia in this context is not a sign of parasitic infection (the most common cause of significant eosinophilia globally) but rather a marker of persistent Type 2 allergic inflammation. Successful ABPA treatment with prednisolone and itraconazole typically normalizes eosinophil count as part of the response to treatment. Persistent or rising eosinophilia despite treatment is a warning sign of inadequate ABPA control or treatment-resistant disease.

Patients with ABPA require regular specialist monitoring including: total serum IgE at every clinic visit (every 3 to 6 months when stable) — a rise of more than 50% above nadir predicts relapse; blood eosinophil count at each visit; chest CT annually or during suspected exacerbations to monitor for new mucus plugging, bronchiectasis progression, or HAM; spirometry annually to track airflow limitation; and liver function tests during itraconazole therapy. Patients on prolonged prednisolone therapy need bone density monitoring and blood glucose screening. The monitoring schedule should be individualized by a specialist based on ABPA severity stage and treatment regimen — the above represents a general framework for stable patients.